Fish oil reached the brain. The hoped-for benefit did not follow.
A two-year DHA trial separates biological activity from clinical benefit
High-dose DHA supplementation changed a biological measure in a randomized trial of older adults at risk for dementia. Over two years, however, the researchers did not observe better cognition or brain-volume outcomes than with placebo. The distinction is central to longevity medicine: reaching a target is not the same as improving a life.
The phase IIa trial, published in EBioMedicine, enrolled 365 adults aged 55 to 80 at the University of Southern California. They did not have dementia, consumed little dietary DHA and had at least one dementia risk factor. Participants were randomly assigned to 2 grams of DHA daily or placebo for 24 months. The study was double-blind.
DHA is an omega-3 fatty acid. Nearly half the participants carried APOE ε4, a genetic variant associated with increased Alzheimer's risk. Researchers were interested in whether supplementation could change DHA availability in the central nervous system, including among carriers.
What the trial was designed to establish
The primary outcome was a change in the ratio of DHA to arachidonic acid in cerebrospinal fluid at six months. Participants willing to undergo lumbar puncture contributed to that measurement. The ratio increased with DHA compared with placebo, and the difference did not depend on APOE ε4 status.
That was evidence of biological target engagement. It showed that the intervention changed the intended biochemical measure. It did not by itself establish prevention of Alzheimer's disease.
What did not improve
Over 24 months, the researchers found no treatment differences in cognitive performance or brain volumes. Brain imaging was a secondary outcome, and cognition was exploratory. These distinctions matter: the study was built primarily to test the biochemical question rather than to deliver a definitive verdict on every possible clinical benefit.
Dropout was 38%, largely related to COVID-19. That is a substantial limitation. The trial also studied a particular population, dose and formulation. It cannot stand in for every use of omega-3 products, every dietary pattern or every stage of cognitive illness.
The absence of a detected benefit is not a demonstration that fish is useless or that a whole dietary pattern has no value. Those are different questions. Nor should the result be repackaged as proof that the supplement prevented decline simply because a blood or spinal-fluid marker changed.
The lesson for longevity
The study makes a valuable demand of future interventions: show what happens beyond the mechanism. Better biological access can be an important step, but people ultimately care about memory, independence and daily function.
The investigators suggest that future research should focus on how the brain handles DHA. For readers, the immediate implication is to distinguish the reason a supplement might work from evidence that it delivers the outcome being promised. Decisions about an existing treatment or supplement should account for its actual indication and a person's clinical circumstances.
Read the research: Primary study / PubMed
Study publication: July 2026. Source edition: October 23, 2026.